Literature DB >> 2410717

Studies on the mechanism of the positive inotropic effect of piroximone in cat papillary muscle.

H C Cheng, T Kariya, E M Gleason, R C Dage.   

Abstract

The mechanism of the inotropic effect of piroximone HCl [MDL 19205A, 4-ethyl-1,3-dihydro-5-(4-pyridinylcarbonyl)-2H-imidozol-2-on e HCl] was studied in the cat papillary muscle paced electrically in vitro. Piroximone produced a concentration-dependent positive inotropic effect accompanied by an increase in rate of contraction and rate of relaxation, but abbreviated time to peak tension and relaxation time. The positive inotropic effect produced by piroximone was antagonized by carbachol, 3 X 10(-6) M, whereas that produced by increasing calcium concentration was not affected by carbachol. In potassium chloride (22 mM) depolarized muscle, piroximone restored contractility, which was not affected by propranolol (10(-6) M) or by tetrodotoxin (2 X 10(-5) M), but was inhibited by nifedipine (10(-7) M). Piroximine also elevated tissue cyclic AMP (cAMP) content in the papillary muscle. Although nifedipine inhibited the restoration of contractility, it did so without altering the increase of cAMP produced by piroximone. These results suggest that piroximone causes an increase in calcium influx that is mediated by an increase in cAMP, and the results are consistent with the hypothesis that specific inhibition of the high affinity cAMP phosphodiesterase (PDE III) plays a role in the positive inotropic effect of piroximone.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410717     DOI: 10.1097/00005344-198507000-00020

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle.

Authors:  M Galvan; C Schudt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

2.  Pharmacokinetics of piroximone (MDL 19.205) in healthy volunteers.

Authors:  K D Haegele; G G Belz; T T Meinicke; P J Schechter
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.

Authors:  H von der Leyen
Journal:  Klin Wochenschr       Date:  1989-06-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.